← Back to Search

Prescreening Group for Stargardt Disease

N/A
Recruiting
Research Sponsored by Ascidian Therapeutics, Inc
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 4 years
Awards & highlights

Summary

This is an observational prescreening study. Individuals who are eligible for prescreening will undergo testing procedures that may be used to determine eligibility in ACDN-01 clinical trials.

Eligible Conditions
  • Stargardt Disease
  • Cone Rod Dystrophy
  • Macular Degeneration

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~4 years
This trial's timeline: 3 weeks for screening, Varies for treatment, and 4 years for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Confirm mutations in the ABCA4 gene
Confirm the absence of pathogenic mutations in genes known to cause retinal disease other than ABCA4-related retinopathy
Historical BCVA/LLVA measurements
+4 more

Trial Design

1Treatment groups
Experimental Treatment
Group I: Prescreening GroupExperimental Treatment1 Intervention
The prescreening study consists of genetic and visual assessments and will require at least 1 onsite visit. All clinical assessments performed are for the purpose of determining research eligibility for ACDN-01 clinical trials.

Find a Location

Who is running the clinical trial?

Ascidian Therapeutics, IncLead Sponsor
1 Previous Clinical Trials
13 Total Patients Enrolled
1 Trials studying Stargardt Disease
13 Patients Enrolled for Stargardt Disease
Alia RashidStudy DirectorAscidian Therapeutics
1 Previous Clinical Trials
13 Total Patients Enrolled
1 Trials studying Stargardt Disease
13 Patients Enrolled for Stargardt Disease
~33 spots leftby Aug 2027